Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 15 | 2024 | 546 | 1.870 |
Why?
|
| Neurologic Examination | 5 | 2024 | 127 | 1.240 |
Why?
|
| Antiparkinson Agents | 7 | 2015 | 40 | 1.180 |
Why?
|
| Virtual Reality | 1 | 2024 | 65 | 0.820 |
Why?
|
| Huntington Disease | 5 | 2025 | 63 | 0.720 |
Why?
|
| Tai Ji | 1 | 2020 | 4 | 0.680 |
Why?
|
| Qigong | 1 | 2020 | 2 | 0.680 |
Why?
|
| Acupuncture Therapy | 1 | 2020 | 22 | 0.660 |
Why?
|
| Yoga | 1 | 2020 | 32 | 0.660 |
Why?
|
| Medical Marijuana | 1 | 2020 | 123 | 0.580 |
Why?
|
| Carbidopa | 3 | 2015 | 8 | 0.580 |
Why?
|
| Levodopa | 4 | 2015 | 38 | 0.570 |
Why?
|
| Tardive Dyskinesia | 1 | 2017 | 1 | 0.550 |
Why?
|
| Tetrabenazine | 1 | 2017 | 5 | 0.550 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2017 | 8 | 0.550 |
Why?
|
| Valine | 1 | 2017 | 79 | 0.530 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 1048 | 0.420 |
Why?
|
| Antipsychotic Agents | 3 | 2017 | 205 | 0.400 |
Why?
|
| Biological Availability | 2 | 2009 | 138 | 0.340 |
Why?
|
| Friedreich Ataxia | 2 | 2022 | 77 | 0.330 |
Why?
|
| Clinical Trials as Topic | 4 | 2022 | 1033 | 0.300 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2009 | 13 | 0.300 |
Why?
|
| Torticollis | 3 | 2005 | 16 | 0.300 |
Why?
|
| Quinolones | 1 | 2009 | 135 | 0.260 |
Why?
|
| Piperazines | 1 | 2009 | 349 | 0.250 |
Why?
|
| Neurological Rehabilitation | 1 | 2025 | 10 | 0.230 |
Why?
|
| Motor Skills | 2 | 2025 | 100 | 0.230 |
Why?
|
| Music Therapy | 1 | 2025 | 25 | 0.230 |
Why?
|
| Movement | 2 | 2024 | 283 | 0.230 |
Why?
|
| Magnetoencephalography | 1 | 2025 | 154 | 0.220 |
Why?
|
| Eye Movements | 1 | 2024 | 82 | 0.220 |
Why?
|
| Hand | 1 | 2024 | 160 | 0.200 |
Why?
|
| Psychomotor Performance | 1 | 2024 | 316 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2024 | 124 | 0.180 |
Why?
|
| Head Movements | 1 | 2001 | 24 | 0.180 |
Why?
|
| Dronabinol | 1 | 2024 | 237 | 0.170 |
Why?
|
| Patients | 1 | 2002 | 176 | 0.160 |
Why?
|
| Humans | 29 | 2025 | 138651 | 0.160 |
Why?
|
| Palliative Care | 2 | 2024 | 814 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2020 | 90 | 0.160 |
Why?
|
| Oxidoreductases | 1 | 2019 | 96 | 0.150 |
Why?
|
| Scoliosis | 1 | 2021 | 214 | 0.140 |
Why?
|
| Caregivers | 2 | 2024 | 904 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2024 | 10938 | 0.130 |
Why?
|
| Ubiquinone | 1 | 2016 | 31 | 0.130 |
Why?
|
| Health Status | 1 | 2002 | 820 | 0.120 |
Why?
|
| Observer Variation | 3 | 2002 | 351 | 0.120 |
Why?
|
| Adult | 13 | 2025 | 38296 | 0.120 |
Why?
|
| Suspensions | 1 | 2015 | 27 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2015 | 44 | 0.120 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2016 | 44 | 0.120 |
Why?
|
| Male | 19 | 2025 | 68216 | 0.120 |
Why?
|
| Vitamins | 1 | 2016 | 188 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 903 | 0.110 |
Why?
|
| Telemedicine | 1 | 2024 | 863 | 0.110 |
Why?
|
| Middle Aged | 17 | 2025 | 33792 | 0.110 |
Why?
|
| Hypokinesia | 2 | 2011 | 11 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 708 | 0.110 |
Why?
|
| Female | 18 | 2025 | 73913 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 373 | 0.110 |
Why?
|
| Cannabis | 1 | 2020 | 501 | 0.100 |
Why?
|
| Physicians | 1 | 2002 | 927 | 0.100 |
Why?
|
| Aged | 13 | 2024 | 24182 | 0.100 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2011 | 20 | 0.090 |
Why?
|
| Indans | 1 | 2011 | 12 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2019 | 1454 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2011 | 29 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 2045 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2024 | 1946 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1486 | 0.080 |
Why?
|
| Catechols | 1 | 2009 | 15 | 0.080 |
Why?
|
| Aripiprazole | 1 | 2009 | 21 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2017 | 1091 | 0.070 |
Why?
|
| Nitriles | 1 | 2009 | 178 | 0.070 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2005 | 50 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2009 | 5160 | 0.060 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2005 | 8 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 85 | 0.060 |
Why?
|
| Time | 1 | 2005 | 88 | 0.060 |
Why?
|
| Neuromuscular Agents | 1 | 2005 | 39 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2004 | 57 | 0.050 |
Why?
|
| Botulinum Toxins | 1 | 2005 | 44 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 419 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2007 | 1053 | 0.050 |
Why?
|
| Neurologists | 1 | 2024 | 22 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 13322 | 0.050 |
Why?
|
| Quality of Life | 2 | 2024 | 2954 | 0.050 |
Why?
|
| Dopamine | 1 | 2004 | 308 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2019 | 7639 | 0.040 |
Why?
|
| Disability Evaluation | 3 | 2011 | 298 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2007 | 460 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 2838 | 0.040 |
Why?
|
| Reference Standards | 1 | 2001 | 184 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2025 | 666 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2025 | 970 | 0.040 |
Why?
|
| Acetamides | 1 | 2001 | 37 | 0.040 |
Why?
|
| Learning | 1 | 2004 | 418 | 0.040 |
Why?
|
| Dyskinesias | 1 | 2000 | 20 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 519 | 0.040 |
Why?
|
| Medical Records | 1 | 2000 | 183 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2001 | 407 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 3311 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 2861 | 0.040 |
Why?
|
| Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2016 | 15860 | 0.040 |
Why?
|
| Clozapine | 1 | 1998 | 21 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 378 | 0.040 |
Why?
|
| Neurocognitive Disorders | 1 | 1998 | 30 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 534 | 0.030 |
Why?
|
| Cognition | 1 | 2004 | 1176 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2024 | 1434 | 0.030 |
Why?
|
| Muscle Spasticity | 1 | 1996 | 61 | 0.030 |
Why?
|
| Research Design | 1 | 2022 | 1120 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 204 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 96 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 303 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 412 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 286 | 0.030 |
Why?
|
| Brain | 1 | 2007 | 2782 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2000 | 640 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 2039 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2744 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2734 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1285 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 7683 | 0.020 |
Why?
|
| Time Factors | 3 | 2011 | 6877 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 21528 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2007 | 66 | 0.020 |
Why?
|
| Association Learning | 1 | 2007 | 63 | 0.020 |
Why?
|
| Education | 1 | 2007 | 111 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 84 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 5729 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 37309 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2004 | 38 | 0.010 |
Why?
|
| Feedback, Psychological | 1 | 2004 | 23 | 0.010 |
Why?
|
| United States | 2 | 2016 | 15018 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 3998 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2005 | 149 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2005 | 299 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 309 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2004 | 159 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 539 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2004 | 248 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2007 | 768 | 0.010 |
Why?
|
| Receptors, Glutamate | 1 | 2001 | 26 | 0.010 |
Why?
|
| Child | 1 | 2021 | 21883 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 679 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 994 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 308 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2001 | 599 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 1859 | 0.010 |
Why?
|
| Patient Admission | 1 | 1998 | 202 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1998 | 574 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 10398 | 0.010 |
Why?
|